Ara
Toplam kayıt 4, listelenen: 1-4
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
(NLM (Medline), 2022)
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This ...
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ...
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: Cross-sectional data from the psoriatic arthritis-international database
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis ...
Clinical and laboratory factors associated with bamboo spine in patients with axial spondyloarthritis: are there clues for bamboo spine?
(Clinical and Experimental Rheumatology S.A.S., 2023)
Objective To analyse the clinical and laboratory factors associated with bamboo spine. Methods Data of patients fulfilling the 2009 ASAS classification criteria for axial spondyloarthritis, registered in the national, ...